The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered entities that dispense discounted medications through their contract pharmacy partners. The move is a significant escalation of the current standoff between the federal government and the six manufacturers.
The companies being referred are AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, United Therapeutics and Sanofi. The letters noted that HRSA had asked each of them last spring to immediately resume offering 340B pricing to the contract pharmacies, noting that they faced civil monetary penalties for refusing to do so. All of the letters – signed by HRSA’s Acting Director of the Office of Pharmacy Affairs Michelle Herzog – made note of each manufacturer’s “continued refusal to comply.”
The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (OIG) regarding their refusal to offer 340B program discounts to 340B covered entities that dispense discounted medications through their contract pharmacy partners.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
